Johnson & Johnson’s RYBREVANT® and LAZCLUZE™ Show Promising Results in Advanced Lung Cancer Treatment
$JNJ
Johnson & Johnson (NYSE: JNJ) has announced significant results from the MARIPOSA study, highlighting the effectiveness of RYBREVANT® (amivantamab-vmjw) in combination with LAZCLUZE™ (lazertinib) for treating advanced non-small cell lung cancer (NSCLC). This Phase 3 trial presents a chemotherapy-free approach that outperforms osimertinib monotherapy in patients with specific epidermal growth factor receptor (EGFR) mutations, offering new hope in the fight against this aggressive cancer.
The study, involving 1,074 patients, revealed a 61% survival rate with the combination therapy after a median follow-up of 31.1 months, compared to 53% for those treated with osimertinib. These findings, presented at the 2024 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (IASLC), also demonstrate significant improvements in progression-free survival and better control over central nervous system (CNS) disease.
RYBREVANT® and LAZCLUZE™ not only extend overall survival but also show improved intracranial progression-free survival, with more patients in the combination group avoiding the need for additional therapies compared to those receiving osimertinib. These promising outcomes underscore the potential of the combination therapy as a new standard for treating NSCLC.
In recognition of these results, the US Food and Drug Administration (FDA) has granted the combination therapy a Priority Review designation. Furthermore, the therapy is now recommended in the NCCN Guidelines as a preferred first-line treatment for NSCLC patients with EGFR exon 19 deletions or L858R mutations.
Beyond the MARIPOSA study, RYBREVANT® is under investigation in multiple clinical trials for various stages of NSCLC, evaluating its effectiveness when paired with other therapies and exploring alternative administration methods, such as subcutaneous delivery. These efforts aim to further expand the application of RYBREVANT® and improve patient outcomes.
Johnson & Johnson’s commitment to revolutionizing cancer treatment is evident in its ongoing research and development of innovative therapies like RYBREVANT® and LAZCLUZE™. As the company continues to push the boundaries of cancer care, it seeks to improve survival rates and enhance the quality of life for patients facing the challenges of advanced NSCLC.
**DISCLAIMER: THIS CONTENT IS FOR INFORMATIONAL PURPOSES ONLY AND SHOULD NOT BE INTERPRETED AS INVESTMENT ADVICE. INVESTING INVOLVES RISK, INCLUDING THE POTENTIAL LOSS OF PRINCIPAL. READERS ARE ENCOURAGED TO CONDUCT THEIR OWN RESEARCH AND CONSULT WITH A QUALIFIED FINANCIAL ADVISOR BEFORE MAKING ANY INVESTMENT DECISIONS.**